View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 9, 2021

Roche to withdraw US indication for Tecentriq in bladder cancer

Roche is set to voluntarily withdraw the US indication for Tecentriq (atezolizumab) in prior platinum treated metastatic urothelial carcinoma (mUC, bladder cancer) following its consultation with the US Food and Drug Administration (FDA).

Roche is set to voluntarily withdraw the US indication for Tecentriq (atezolizumab) in prior platinum treated metastatic urothelial carcinoma (mUC, bladder cancer) following its consultation with the US Food and Drug Administration (FDA).

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

The company held discussions with the FDA as part of a review of accelerated approvals with confirmatory trials that did not meet primary endpoint(s) and are yet to get regular approvals.

A monoclonal antibody, Tecentriq can potentially attach with a Programmed Death Ligand-1 (PD-L1) protein, which is expressed on tumour cells and tumour-infiltrating immune cells, inhibiting its interactions with both PD-1 and B7.1 receptors.

Roche will work with the FDA in the coming weeks to conclude the withdrawal process.

The decision does not impact other approved indications for Tecentriq. Healthcare specialists are being informed by the company of its withdrawal.

Roche noted that patients currently receiving Tecentriq for prior-platinum treated mUC should talk to their healthcare provider.

Roche chief medical officer and global product development head Levi Garraway said: “The Accelerated Approval Program allows people with difficult-to-treat cancers to receive certain new therapies earlier.

“While the withdrawal of Tecentriq for prior-platinum treated bladder cancer is disappointing, Tecentriq continues to demonstrate benefits across multiple cancer types and therefore remains a meaningful treatment option for many patients.”

The Accelerated Approval Program of FDA permits conditional approval of a treatment for an unmet medical need for a serious illness, with specific post-marketing requirements (PMRs) to ascertain its clinical benefit and convert to regular approval.

In 2016, Tecentriq received accelerated approval for treating prior-platinum treated mUC based on results from the IMvigor210 study (Cohort 2).

Continued approval for the indication depended upon the results of the IMvigor211 study, which failed to meet its primary endpoint of overall survival in the high PD-L1 subjects.

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology